We read with great interest the article by Stepanova et al. 1 In this report from the United States with 10,582 eligible individuals (1.52% of whom were positive for hepatitis C virus [HCV] antibody [anti-HCV]), the rate of insurance coverage was significantly lower in patients with HCV infection (6
Hepatitis C virus: evasion of the interferon-induced antiviral response
β Scribed by Deborah R. Taylor
- Book ID
- 105797185
- Publisher
- Springer
- Year
- 2000
- Tongue
- English
- Weight
- 207 KB
- Volume
- 78
- Category
- Article
- ISSN
- 0946-2716
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract The aim of this study was to elucidate indicator of interferon (IFN) therapy for reducing hepatocellular carcinoma (HCC) in chronic hepatitis C patients without eradicating hepatitis C virus (HCV) RNA during IFN therapy. Inclusion criteria were biopsyβproven chronic hepatitis or liver c
The anti-inflammatory and antiapoptotic heme degrading enzyme heme oxygenase-1 (HO-1) has been shown recently to interfere with replication of hepatitis C virus (HCV). We investigated the effect of HO-1 products carbon monoxide (CO), iron and biliverdin on HCV replication using the replicon cell lin